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scarce health resources has been emphasized both in the litera-
ture and in decision-making practices globally. As an interna-
tional academic journal, Value in Health Regional Issues (ViHRI) is
taking its place in facilitating the exchange of ideas, theories,
experiences, and empirical ﬁndings in regard to evidence-based
approaches.
ViHRI for Asia has now entered its fourth year. Over the last 4
years, the journal has made notable progress in terms of quantity
and quality of manuscripts submitted. The breadth of subject
areas has expanded to cover topics of economic evaluation,
comparative effectiveness analysis and health technology assess-
ment, health policy, quality of life, patient-reported outcomes,
methodology, and conceptual dialogue.
As with the 2014 Asia volume, most of the studies included in
this 2015 volume remain typical of health economics and out-
comes research, including cost-effectiveness, burden of disease,
costing, and patient-reported outcome studies. Two-thirds (14 of
21; 67%) of this volume’s accepted manuscripts fall into these
typical groupings, which is similar to the proportion of 65% (20 of
31) that we saw in the 2014 volume. A conspicuous change was
noted, however, in the proportion of studies in the ﬁeld of health
system and policy research. Compared with its proportion of 16%
in the 2014 volume (5 health policy studies out of 31 accepted
manuscripts), we now have 29% in the 2015 volume (6 of 21). Such
a big growth in this ﬁeld’s representation was neither intended
nor anticipated by the ViHRI editorial team. One explanation is
that the increased proportion of health policy studies could be a
reﬂection of an enhanced level of recognition among researchers
in Asia of the importance of health policy as a way of effectively
inﬂuencing health resource allocation. Considering the policy
trend in many Asian countries of adopting and strengthening
health technology assessment frameworks, this would not be
surprising.
The focus of those policy articles ranges from very country-
speciﬁc (i.e., South Korea, China) to cross-country comparisons.
Three of the six policy studies compare policy facets of more than
three Asian countries. This can be considered a very positive
trend of research works development and dissemination in the
Asia-paciﬁc region because the linkage of scientiﬁc evidence and
policy needs to be present so that the ﬁndings can be used for
health policy–level decision making. One major article falling in
the category of health policy analysis (by Thorat, Lin, and
Neumann, this volume) was a description of the state of cost-
utility analysis (CUA) in Asia. Because CUA has been recognized
widely to be one of the most common forms of economic
evaluation studies, this study gives a very clear trend of changesial support: The authors have no other ﬁnancial rin the overall quality of health economics conducted in the
region. The study revealed that CUAs generally followed standard
methodological practices. It highlighted the need for improve-
ment in certain areas such as disclosing funding status, reporting
the currency year used in the analysis, and performing sensitivity
analysis. Another example of cross-country comparison is the
study by Cook and Kim (this volume), which compares the
processes and timing of regulatory and subsidized access system
across seven jurisdictions–Australia, China, Japan, South Korea,
New Zealand, Taiwan, and Thailand. These comparative studies
submitted to and published by ViHRI indicate that the journal
may be starting to function as a platform for policy development
in the Asia region.
Contrary to such multicountry studies is the submission of
country adaptation manuscripts in the areas of economic evalua-
tions and outcomes research. It turned out that several of the
submitted manuscripts for the 2015 volume fell under the
category of country adaptation, that they used a model that
was previously developed for an evaluation of a given interven-
tion in another country, or that they simply tried to validate a
quality-of-life instrument into another language or in a different
jurisdiction. ViHRI hardly excludes such manuscripts from pub-
lication, but only if they make signiﬁcant independent scientiﬁc
contributions to the existing literature.
ViHRI Asia 2015 received 63 manuscript submissions in total.
Twenty-one have been accepted, 24 rejected, and 1 manuscript
has been withdrawn, whereas the rest are still under editorial
review as of April 2015. Two manuscripts have been recom-
mended for submission to ISPOR Connections (renamed now as
ISPOR Value and Outcomes Spotlight) during the editorial process.
Manuscripts were submitted from a diverse geographic range,
including Australia, Iran, Mongolia, Iraq, Indonesia, India, the
Philippines, Vietnam, Thailand, Malaysia, mainland China, Sin-
gapore, Taiwan, Japan, and South Korea. Overall, the submissions
indicated that the quality of scientiﬁc research and analysis from
the Asia-Paciﬁc region has grown and could well be matched to
that of its western counterpart. Many of the studies also showed
ease in translating analytical ﬁndings into policy development.
One editorial aspect our editorial team would like to share
with the authors is the issue of the language barrier. As we are
well aware, English is a second language to almost all the authors
from Asia, and a conspicuous language barrier exists in manu-
scripts written by these researchers. In many manuscripts, the
poorly written English often times does not do justice to the well-
done research. Often times the editorial team ﬁnds itself fully
supporting the arguments and ﬁndings of a study but the poor
write-up in English prevents us from publishing the study. Inelationships to disclose.
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clarify their thoughts, ideas, and scientiﬁc rationale in English
through manuscript revision and rewriting. Most reviewers feel
that providing comments for language editing and restructuring
of writing is cumbersome and beyond the scope of what they
could do. As a consequence, reviewers quickly recommend
rejection of such manuscripts. It is therefore important for
authors to check and recheck their writing before submitting
manuscripts. Seeking professional English language editing assis-
tance could also help bring a manuscript to acceptable standards
of coherence and eloquence.
Selecting manuscripts for publication is never easy. In gen-
eral, accepted manuscripts meet three general qualiﬁcations—
good science, logical sequence in arguments and presentation,
and reasonable writing. There is one additional dimension,
however, that we value for ViHRI publication. It is important to
ViHRI to deliver a balanced and objective view through its
published articles. We feel that this dimension is a crucial
prerequisite for this journal to be appreciated by a diverse
audience in the health care arena. Carrying an unbiased view in
an academic journal in health care is particularly challenging
because there are truly multiple stakeholders in health care—
policymakers, commercial industry, consumers, providers, aca-
demics, corporate consultants, public researchers. Each stake-
holder is engaged in the decision-making process and most likely
each one is committed to its point of view.
For example, the pharmaceutical industry may possess its own
view on a given health budget allocation scheme, which could be
somewhat different from what public policy makers are pursuing
to maximize the public’s health status. Meanwhile, consulting
ﬁrms may try to reﬂect the views held by sponsors, in many cases
that of commercial industry, whereas general consumers—your
everyday patients—could be in favor of policy directions deemed
necessary by public policy making. Furthermore, the voice of
patient advocacy for the general public could be in conﬂict with
views held by disease-speciﬁc patient advocacy because the two
could compete for use of the limited pool of available resources.
The former may favor a fairer allocation of health funds among all
participants, whereas the latter could insist on higher priority
allocation of funds to protect patients with speciﬁc diseases, say,
cancer or end-of-life disease. Another inherent complexity is that
the latter’s arguments often coincide with the views held by the
industry that supplies the product in question. Even more complex
is when the views held by health care providers—hospitals and
physicians as prescribers—are taken into consideration. Their
views are often divided because some providers support theindustry and disease-speciﬁc patient advocacy position that an
individual life has to be saved no matter what, whereas others
warn of excessive spending by certain population groups that will
leave other potential patients less attended [1].
Complexity of differentiated views even among international
organizations was well reported in a recent publication [2].
Although in a different setting, it describes difﬁculties and
complexities involved in access to medical technologies [2].
Under such a complex and diverse spread of viewpoints among
stakeholders in health care, both at the domestic level and at the
global level, it is imperative for our journal to maintain balance
and objectivity, striving to publish only those articles that present
objective discussions and draw unbiased conclusions based on
scientiﬁc evidence. Doing so is a signiﬁcant challenge for most
health outcome–related journals, but especially for a young
journal such as ViHRI that faces the added burden of maintaining
a reasonable review capacity. As a source of scientiﬁc informa-
tion, we would like to gain the reputation that ViHRI is one that is
reliable, in which only objective and balanced views can be
found. ViHRI will faithfully continue to pursue such objectivity
through its editorial process.
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